William L Delaat
United States of America
Will has been a member of the Board of Directors since June 2008. He has more than 35 years’ experience in the global pharmaceutical industry, most recently as the Managing Director of the Australian subsidiary of Merck & Co, a position he held from 1997 until his retirement in 2008. During his career Will has held executive positions in both Europe and Australia for Merck and AstraZeneca. He has a broad depth of experienced in pharmaceutical sales and marketing and has been responsible for numerous international product launches. Will was Chairman of the pharmaceutical peak body Medicines Australia, and the Pharmaceuticals Industry Council from 2008-2012. He is also the former Chairman of EnGeneIC Ltd, an unlisted Australian biotech company, and a director of the George Institute for Global Health Board. Will holds a Bachelor of Science, Physiology & Chemistry, from the University of London. Will is Chair of the Pharmaxis Audit Committee and a member of the Remuneration and Nomination Committee.
Pharmaxis is a pharmaceutical research company focussed on inflammation and fibrosis with a portfolio of products at various stages of development and approval.